Literature DB >> 24711667

Wim van den Brink and colleagues reply to Des Spence and Alain Braillon.

Wim van den Brink1, Karl Mann, Antoni Gual, Henri-Jean Aubin.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24711667     DOI： 10.1136/bmj.g2605

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

Review 1.  Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.

Authors:  Niamh Fitzgerald; Kathryn Angus; Andrew Elders; Marisa de Andrade; Duncan Raistrick; Nick Heather; Jim McCambridge
Journal:  Addiction       Date:  2016-06-05       Impact factor: 6.526
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.